Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Combination Immunotherapy and Antifungal Chemotherapy

David A. Stevens
Clinical Infectious Diseases
Vol. 26, No. 6 (Jun., 1998), pp. 1266-1269
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/4460370
Page Count: 4
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
Combination Immunotherapy and Antifungal Chemotherapy
Preview not available

Abstract

Historical clinical observations suggested that cellular immunity is central in the outcome of deep fungal infections, and experimental observations later proved this. Unstimulated effector cells interact synergistically with antifungal drugs. Recombinant cytokines, of which interferon γ (IFN-γ) is the most prominent, stimulate several host-effector cells (macrophages, monocytes, neutrophils) for antifungal activity. Effector cells stimulated by such molecules (data with macrophage colony-stimulating factor, granulocyte colony-stimulating factor, and granulocyte-macrophage colony-stimulating factor with azoles are presented as examples) also have enhanced synergistic activity with antifungals. A tilt toward a type 1 T-helper (Th1) cell pathway seems essential in antifungal host defenses. Cytokines (and anticytokines) that promote this pathway can be protective in vivo and act cooperatively with antifungal drugs. Observations with interleukin (IL)-12, IFN-γ, and anti-IL4 illustrate this. The clinical applications of these strategies are just beginning.

Page Thumbnails

  • Thumbnail: Page 
1266
    1266
  • Thumbnail: Page 
1267
    1267
  • Thumbnail: Page 
1268
    1268
  • Thumbnail: Page 
1269
    1269